Nashville, Tenn., August 5, 2013 – Insight Genetics today announced that it has added four new team members:

- David Burg is Associate Director, Business Development;

- Dan Bailey, MBA, is Senior Associate, New Product Planning;

- Tyler Nielsen, MBS, is Research Associate III; and

- Lindsay Chatfield is Research Associate I;

Since its founding in 2007, Insight Genetics has been dedicated to enabling precision medicine in cancer care. The company collaborates with researchers, clinicians, and drug developers to develop molecular diagnostics that aid physicians in precisely typing and effectively treating patients’ cancers.

“We are pleased to have David, Dan, Tyler and Lindsay join our team,” said Christopher Callaghan, President and COO of Insight Genetics. “Each of these professionals brings a breadth of knowledge and expertise that will enhance our research and business development operations. We look forward to the contributions each will make to our company’s growth and the advancement of personalized cancer care.”

As Associate Director of Business Development, David Burg will lead the sales and marketing programs of Insight Genetics’ CLIA-certified laboratory, Insight Molecular Labs. Prior to joining Insight Genetics, Burg was Regional Sales Director for Response Genetics, Inc., where he was responsible for the sale of predictive biomarker assays covering 26 western states. Earlier in his career, he was Senior Executive Oncology Account Manager with GlaxoSmithKline.

As Senior Associate of New Product Planning, Dan Bailey will lead the management and administration of Insight Genetics’ proprietary Biomarker Decision Support System and intellectual property portfolio. Bailey interned with Insight Genetics while completing his MBA at Vanderbilt University’s Owen Graduate School of Management. Before pursuing his MBA, he was a technical services engineer for Epic Systems Corporation. Bailey received his B.S. in biomedical engineering from Northwestern University.

As a Research Associate III, Tyler Nielsen will design and conduct experiments as part of the Insight Genetics Research & Development team, contributing to both current projects and those in the pipeline. Nielsen received his M.A. in biomedical science from Des Moines University. Prior to joining Insight Genetics, he gained extensive biotechnology experience working for Pioneer Hi-Bred and Aegis Sciences Corporation.

As a Research Associate I, Lindsay Chatfield will utilize her molecular biology skills to advance projects within the Insight Genetics Research & Development team, including contributing to multiple National Cancer Institute contracts. Joining in the fall of 2012, Chatfield started with Insight Genetics as a research intern before being promoted to Research Associate I. Chatfield graduated with honors from Vanderbilt University with degrees in neuroscience and molecular & cellular biology, and a minor in philosophy.

About Insight Genetics

Insight Genetics is dedicated to improving the lives of cancer patients through advanced molecular diagnostics that enable precision in cancer care. The company specializes in the discovery, development and commercialization of companion diagnostics that detect specific cancer biomarkers and assist in guiding the effective diagnosis and treatment of cancer. Insight partners with leading academic researchers, pharmaceutical and biotechnology companies, clinical reference laboratories, and IVD kit manufacturers to create new standards of care for cancer patients worldwide. www.insightgenetics.com